Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kunal R Chandekar

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
PET Clinics|April 8, 2026
Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer - Current State and Evolving StandardsSwayamjeet Satapathy, Kunal R Chandekar, Nishikant A Damle
Seminars in Nuclear Medicine|December 4, 2025
Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN)Piyush Aggarwal, Swayamjeet Satapathy, Kunal R Chandekar, et al.
World Journal of Radiology|September 26, 2022
Molecular imaging as a tool for evaluation of COVID-19 sequelae - A review of literatureKunal R Chandekar, Swayamjeet Satapathy, Harmandeep Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2025
Efficacy and Safety of [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> Therapy in Patients with SarcomaSanjana Ballal, Mohammad Sakir, Kunal R Chandekar, et al.
Thyroid : Official Journal of the American Thyroid Association|January 27, 2025
Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [<sup>177</sup>Lu]Lu-DOTAGA.FAPi Dimer TherapySanjana Ballal, Madhav Prasad Yadav, Swayamjeet Satapathy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2025
Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [<sup>177</sup>Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trialSwayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2025
<sup>177</sup>Lu-DOTATATE Plus Capecitabine Versus <sup>177</sup>Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 TrialSwayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2023
Head-to-head comparison of [<sup>68</sup>Ga]Ga-DOTA.SA.FAPi with [<sup>18</sup>F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancersSanjana Ballal, Madhav P Yadav, Frank Roesch, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
PET Clinics|April 8, 2026
Prostate-Specific Membrane Antigen Theranostics in Prostate Cancer - Current State and Evolving StandardsSwayamjeet Satapathy, Kunal R Chandekar, Nishikant A Damle
Seminars in Nuclear Medicine|December 4, 2025
Response Evaluation Criteria in Grade 1/2 Neuroendocrine Tumors (RECIN)Piyush Aggarwal, Swayamjeet Satapathy, Kunal R Chandekar, et al.
World Journal of Radiology|September 26, 2022
Molecular imaging as a tool for evaluation of COVID-19 sequelae - A review of literatureKunal R Chandekar, Swayamjeet Satapathy, Harmandeep Singh, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2025
Efficacy and Safety of [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> Therapy in Patients with SarcomaSanjana Ballal, Mohammad Sakir, Kunal R Chandekar, et al.
Thyroid : Official Journal of the American Thyroid Association|January 27, 2025
Long-Term Outcomes in Radioiodine-Resistant Follicular Cell-Derived Thyroid Cancers Treated with [<sup>177</sup>Lu]Lu-DOTAGA.FAPi Dimer TherapySanjana Ballal, Madhav Prasad Yadav, Swayamjeet Satapathy, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2025
Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [<sup>177</sup>Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trialSwayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 8, 2025
<sup>177</sup>Lu-DOTATATE Plus Capecitabine Versus <sup>177</sup>Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 TrialSwayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 29, 2023
Head-to-head comparison of [<sup>68</sup>Ga]Ga-DOTA.SA.FAPi with [<sup>18</sup>F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancersSanjana Ballal, Madhav P Yadav, Frank Roesch, et al.
Pageof 1